Journal of Clinical Oncology
Articles in this Issue
Association of prostate specific antigen (PSA) doubling time (DT) and prostate specific membrane antigen (PSMA) findings in biochemically recurrent prostate cancer (BCR).
33 Background: Historically, PSA DT can be prognostic for metastasis free survival in BCR (as defined on computed tomograp...
Treatment utilization in metastatic renal cell carcinoma (mRCC) following implementation of a national cancer drug list (CDL) drug reimbursement program in Singapore: A real-world single-centre study.
482 Background: Immune checkpoint inhibitor (ICI) based combination therapy and Cabozantinib have shown overall survival b...
<i>MTAP</i> loss in sarcomatoid renal cell carcinoma (srcRCC): A genomic landscape study.
529 Background: srcRCC is a rare, highly aggressive malignancy with poor prognosis, and thus further exploration of genomi...
Impact of baseline hot flashes on sleep metrics during initial treatment in LIBERTAS clinical trial.
186 Background: Libertas is a study of intermittent ADT administered with apalutamide monotherapy in metastatic castration...
Metformin effects on renal function in mCRPC during PSMA radiopharmaceutical therapy (RPT): A retrospective analysis.
203 Background: Preclinical research indicates that metformin may mitigate renal accumulation of lutetium-177-labeled PSMA...
Prognostic factors affecting racial impact in testicular cancer outcomes in the United States.
591 Background: We previously reported demographics, race, stage, treatment, and survival patterns in testicular cancer (T...
Real-world neoadjuvant therapy utilization and outcomes in patients with muscle-invasive bladder cancer ineligible for cisplatin treatment.
672 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) is standard of care for cisplatin-eligible (CE) patients (p...
Tumor mutational burden to predict overall survival independent of TP53 status in TCGA bladder cancer cohort.
833 Background: Tumor mutational burden (TMB) is an emerging biomarker in bladder cancer and is linked to response to immu...
Availability of clinical trials investigating prostate cancer (PC) in the United States (US).
43 Background: Availability of clinical trials for advanced cancers in the US varies greatly by geographical region, with...
SOLACE: A phase 1 pharmacokinetic, dosimetry, safety, and dose optimization study for a single dose of <sup>153</sup> Sm-DOTMP to treat metastatic bone pain.
TPS271 Background: With patients with bone metastases commonly report pain and significant degradations in quality of life...
Optimizing docetaxel bladder penetration following gemcitabine pretreatment: An analysis of concentration and timing protocols.
785 Background: Shortage and suboptimal efficacy of BCG has spurred the development of novel treatments for patients with...
Association of renal function in non-hydronephrotic patients receiving PD-1 ICIs for bladder cancer with treatment response.
767 Background: Renal insufficiency in bladder cancer (BC) patients is often attributed to hydronephrosis, yet it can also...
Skeletal-related event impact on prostate cancer mortality in the older population in the US: A 24-year trend regression analysis.
58 Background: Skeletal-related events (SREs) are a common cause of morbidity and mortality in metastatic castration-resis...
CONSOLIDATE: A phase I/II study of radiotherapy combined with enfortumab vedotin (EV) for locally advanced bladder cancer with paired translational ctDNA and utDNA.
TPS912 Background: Locally advanced muscle invasive bladder cancer (LA-MIBC) is currently treated with sequential lines of...
Circulating angiogenic–myeloid cytokine axis to predict benefit from first-line immune-checkpoint inhibitor combinations in metastatic clear cell renal cell carcinoma.
550 Background: Metastatic clear cell renal cell carcinoma (ccRCC) first-line treatment relies on immune checkpoint inhibi...
Neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC): SURE-02 primary analysis and biomarker results.
769 Background: Standard-of-care treatment for MIBC is radical cystectomy (RC) with neoadjuvant chemotherapy (CT), but ~50...
Consensus guidance on early identification and management of peripheral neuropathy in patients with UC receiving enfortumab vedotin: A Delphi study.
661 Background: Peripheral neuropathy (PN) is a cumulative, debilitating, and potentially dose-limiting adverse event asso...
Activity and biomarker analyses with casdatifan (cas), a next-generation HIF-2α inhibitor, in refractory clear cell renal cell carcinoma (ccRCC): Results from ARC-20.
493 Background: HIF-2α is a validated target in refractory ccRCC. ARC-20 is an open-label platform study evaluating Cas, a...
Insulin pathway changes in localized prostate cancer: A multi-institutional analysis.
380 Background: Prostate cancer is a heterogeneous disease with variable clinical outcomes. If localized, the patient may...
Treatment patterns and outcomes with second line (2L) therapies in patients (pts) with advanced urothelial carcinoma (aUC) previously treated with first line (1L) enfortumab vedotin (EV) with pembrolizumab (pembro).
676 Background: EV+pembro has significantly transformed 1L treatment of aUC and has become the standard of care. Treatment...
Real-world comparative outcomes of enfortumab vedotin plus pembrolizumab versus platinum-based chemotherapy in metastatic urothelial carcinoma.
778 Background: Enfortumab vedotin (EV) plus pembrolizumab (Pem) has demonstrated superior efficacy in clinical trials for...
Characterization of depth and durability of response in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) who received cabozantinib plus nivolumab (C+N): Long-term follow-up and exploratory analysis of CheckMate 9ER.
508 Background: C+N is approved as first-line treatment in aRCC based on the CheckMate 9ER trial, which demonstrated super...
Circulating tumor DNA (ctDNA) dynamics in bone-dominant metastatic castration resistant prostate cancer (mCRPC) treated with radium-223 with or without olaparib: Biomarker analyses from the multicenter, randomized, phase 2, investigator-initiated COMRADE trial.
158 Background: We previously reported that olaparib significantly improves radiographic progression-free survival (rPFS)...
ASPIRE GCT: A single-arm, phase II clinical trial of aspirin to prevent venous thromboembolism in patients with advanced germ cell tumors receiving chemotherapy.
TPS624 Background: Advanced testicular/germ cell tumors (GCT) are highly curable with chemotherapy; however, patients with...
Clinical burden of recurrence among older adults with muscle invasive bladder cancer undergoing tri-modal therapy in the real world: A SEER-Medicare, population-level study.
679 Background: While radical cystectomy (RC) remains standard of care for muscle-invasive bladder cancer (MIBC), trimodal...